Chadi Nabhan, Chief Medical Officer at Ryght AI, shared on LinkedIn:
“Multiple myeloma treatment continues to evolve, and The SUCCESSOR-2 trial may represent another important step forward.
On Healthcare Unfiltered EXPRESS, I sat down with Dr. Paul Richardson of Dana-Farber Cancer Institute to discuss this phase 3 trial of mezigdomide + carfilzomib + dexamethasone in relapsed/refractory myeloma.
The results are compelling: median PFS was 18.0 vs 8.3 months, translating into a 52% reduction in the risk of progression or death.
But we go beyond the numbers:
- What makes mezigdomide different?
- Where might CELMoDs fit in an increasingly crowded treatment landscape?
- And what could SUCCESSOR-2 mean for clinical practice?
New Healthcare Unfiltered EXPRESS episode.
Please share, discuss, and subscribe.”
You can also read SUCCESSOR-2: Improved PFS and Response Rates With Mezigdomide + Kd vs Kd in R/R Multiple Myeloma on OncoDaily.
